Atsushi Mizokami

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Osteoprotegerin inhibits prostate cancer–induced osteoclastogenesis and prevents prostate tumor growth in the bone

Jian Zhang, Jinlu Dai, Yinghua Qi et al. · Journal of Clinical Investigation · 2001 · 450 citations · Full text

Medicine, Cancer Biology, Oncology +17

Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues.

Noriko Kimura, Atsushi Mizokami, Toshina Oonuma et al. · Journal of Histochemistry & Cytochemistry · 1993 · 306 citations · Full text

Medicine, Biomedical Sciences, Endocrinology +15

Cloning and Characterization of Androgen Receptor Coactivator, ARA55, in Human Prostate

Naohiro Fujimoto, Shuyuan Yeh, Hong‐Yo Kang et al. · Journal of Biological Chemistry · 1999 · 293 citations · Full text

Life Sciences, Endocrinology, Molecular Biology +16

Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2‐induced STAT3 activation

Kouji Izumi, Lei‐Ya Fang, Atsushi Mizokami et al. · EMBO Molecular Medicine · 2013 · 253 citations · Full text

Medicine, Molecular Biology, Oncology +17